Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of MK-7262 and Enlicitide in Healthy Participants
NCT07619443Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of gefapixant and enlicitide (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity at 8 days and Maximum Plasma Concentration at 8 days. Started Jul 2026; status: completed.
02
Drugs
gefapixantenlicitide
Beyond the preview
Go deeper on NCT07619443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619443.